文献速递炎症性肠病

赛妥珠单抗聚乙二醇诱导和维持治疗克罗恩病患者的暴露-反应关系

Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2017-11-21

研究纳入9项临床试验中2157例接受赛妥珠单抗聚乙二醇(CZP)治疗的成人克罗恩病患者,用群体药代动力学模型模拟CZP浓度并评估其与第6周和第26周疗效的关系。结果显示第6周较高的CZP浓度与第6周和第26周的复合结局相关(P<.001),第6周约≥36.1 μg/mL及第12周约≥14.8 μg/mL的浓度与第6周和第26周结局相关。结论认为CZP在克罗恩病中存在暴露-反应关系,达到较高浓度可能增加获得疗效结局的可能性,但尚待前瞻性评估。

要点

  • 第6周较高的CZP浓度与第6周和第26周的复合结局相关(P<.001)。
  • 第6周CZP浓度约≥36.1 μg/mL时,阳性预测值22.8%、阴性预测值92.7%。
  • 第12周CZP浓度约≥14.8 μg/mL时,阳性预测值28.0%、阴性预测值90.4%。

核心结论

  • 赛妥珠单抗聚乙二醇在克罗恩病中呈现暴露-反应关系,达到较高浓度可能增加获得疗效结局的可能性,但尚待前瞻性评估。

研究设计与样本

  • 基于9项临床试验的群体药代动力学模型模拟研究,纳入2157例接受赛妥珠单抗聚乙二醇治疗的成人克罗恩病患者。

主要发现

  • 第2、4、6周CZP浓度在有临床应答、缓解、CRP≤5 mg/L或FC≤250 μg/g的患者中高于无上述结局者。
  • 多变量分析中,第6周较高的CZP浓度与第6周和第26周的复合结局相关(P<.001)。
  • 暴露-反应关系存在个体差异,第6周CZP浓度约≥36.1 μg/mL与第6周和第26周结局相关(阳性预测值22.8%,阴性预测值92.7%)。
  • 第12周CZP浓度约≥14.8 μg/mL与第6周和第26周结局相关(阳性预测值28.0%,阴性预测值90.4%)。

局限性

  • 原文结论指出该暴露-反应关系尚待前瞻性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapeutic drug monitoring may optimize therapy for Crohn's disease (CD). AIM: To use a population pharmacokinetic model that accounts for the time-varying nature of covariates to simulate certolizumab pegol (CZP) concentrations to evaluate the exposure-response relationship for CZP in Crohn's disease. METHODS: Adults (N = 2157) with Crohn's disease were treated with CZP in nine clinical trials. Simulated CZP concentrations were compared to outcomes at weeks 6 and 26, including Crohn's disease activity index (CDAI) response (decrease from baseline ≥ 100 points), remission (CDAI ≤ 150), C-reactive protein (CRP) ≤ 5 mg/L, faecal calprotectin (FC) ≤ 250 μg/g, and a composite endpoint of CDAI ≤ 150 and FC ≤ 250 μg/g. Multivariable analyses identified covariates associated with outcomes and receiver operating characteristic analyses determined optimal CZP concentrations. RESULTS: CZP concentrations at weeks 2, 4 and 6 were higher in patients with clinical response, remission, CRP ≤ 5 mg/L or FC ≤ 250 μg/g at week 6 than without. In multivariable analyses, higher CZP concentrations at week 6 were associated with the composite outcome at weeks 6 and 26 (P < .001). Although the exposure-response relationship varied among patients, approximate CZP concentrations of at least 36.1 μg/mL (positive predictive value [PPV] 22.8% and negative predictive value [NPV] 92.7%) and at least 14.8 μg/mL (PPV 28.0% and NPV 90.4%) at weeks 6 and 12 were associated with weeks 6 and 26 outcomes. CONCLUSIONS: An exposure-response relationship was apparent for CZP in Crohn's disease and achieving higher CZP concentrations may increase the likelihood of attaining efficacy outcomes, but this remains to be evaluated prospectively.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Vande Casteele N, Feagan BG, Vermeire S, et al. Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease. Aliment Pharmacol Ther. 2017. PMID: 29159893. doi:10.1111/apt.14421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。